Botanical/Drug Interaction Studies Should Be Based On Safety Risk - CHPA
This article was originally published in The Tan Sheet
Executive Summary
"Extensive" investigation of drug-drug interactions for botanical drug products is not necessary unless a safety risk is indicated by adverse event reports or other animal or clinical data, the Consumer Healthcare Products Association asserts.
You may also be interested in...
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA